Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic CRC: Analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Authors
Meinolf Karthaus
Klinikum Neuperlach/ Klinikum Harlaching, Department of Hematology, Oncology, and Palliative Care, Munich, Germany;
Meinolf Karthaus , Greta Sommerhäuser , Annika Kurreck , Alexander Beck , Uli Fehrenbach , Stefan Fruehauf , Ullrich Graeven , Lothar Müller , Alexander Koenig , Ludwig Fischer von Weikersthal , Eray Goekkurt , Siegfried Haas , Arndt Stahler , Volker Heinemann , Swantje Held , Annabel Helga Sophie Alig , Stefan Kasper , Sebastian Stintzing , Tanja Trarbach , Dominik Paul Modest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01991873
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 127)
DOI
10.1200/JCO.2023.41.4_suppl.127
Abstract #
127
Poster Bd #
G5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).
First Author: Beeke Hoppe
Poster
2023 ASCO Annual Meeting
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.
First Author: Kathrin Heinrich
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel